29 July 2019

Amedeo Smart

Independent Medical Education


Subscriber: th..@boehringer-ingelheim.com

HIV Infection

29 July 2019 | n=33

  1. Mahy M, Marsh K, Sabin K, Wanyeki I, et al.
    HIV estimates through 2018: data for decision making.
    AIDS 2019.

  2. Meyers DJ, Cole MB, Rahman M, Lee Y, et al.
    The association of provider and practice factors with HIV ART adherence.
    AIDS 2019.

  3. Wang Y, Brummel SS, Beilstein-Wedel E, Dagnall CL, et al.
    Association between zidovudine-containing antiretroviral therapy exposure in utero and leukocyte telomere length at birth.
    AIDS 2019.

  4. Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, et al.
    Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe.
    AIDS 2019.

  5. Cedarbaum E, Ma Y, Scherzer R, Price JC, et al.
    Contributions of HIV, HCV, and traditional vascular risk factors to peripheral artery disease in women.
    AIDS 2019.

  6. de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, et al.
    A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine.
    AIDS 2019.

  7. Truong HM, O'keefe KJ, Pipkin S, Liegler T, et al.
    How are transgender women acquiring hiv? insights from phylogenetic transmission clusters in San Francisco.
    AIDS 2019.

  8. Wang Z, Molsberry SA, Cheng Y, Kingsley L, et al.
    Cross-sectional analysis of cognitive function in the MACS with multivariate normative comparisons.
    AIDS 2019.

  9. Richert-Spuhler LE, Pattacini L, Plews M, Irungu E, et al.
    Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in HSV-2 seropositive women.
    AIDS 2019.

  10. Clifford DB.
    Thinking about getting older with HIV.
    Clin Infect Dis 2019.

  11. Byrd KK, Hou JG, Hazen R, Kirkham H, et al.
    Antiretroviral Adherence Level Necessary for HIV Viral Suppression using Real-World Data.
    J Acquir Immune Defic Syndr 2019.

  12. Womack JA, Murphy TE, Rentsch CT, Tate JP, et al.
    Polypharmacy, hazardous alcohol and illicit substance use and serious falls among PLWH and uninfected comparators.
    J Acquir Immune Defic Syndr 2019.

  13. Modongo C, Wang Q, Dima M, Matsiri O, et al.
    Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: Programmatic experience from Botswana.
    J Acquir Immune Defic Syndr 2019.

  14. Archampong T, Ojewale O, Bears K, Chen Y, et al.
    Relationship between ABCC4 SNPs and hepatitis B virus suppression during tenofovir-containing antiretroviral therapy in patients with HIV/HBV coinfection.
    J Acquir Immune Defic Syndr 2019.

  15. Haaland RE, Martin A, Livermont T, Fountain J, et al.
    Urine emtricitabine and tenofovir concentrations provide markers of recent antiretroviral drug exposure among HIV-negative men who have sex with men.
    J Acquir Immune Defic Syndr 2019.

  16. Kerr SJ, Puthanakit T, Malee KM, Thongpibul K, et al.
    Increased risk of executive function and emotional-behavioural problems among virologically well-controlled perinatally HIV-infected adolescents in Thailand and Cambodia.
    J Acquir Immune Defic Syndr 2019.

  17. Velloza J, Bacchetti P, Hendrix CW, Murnane P, et al.
    Short and long-term pharmacologic measures of HIV pre-exposure prophylaxis use among high-risk men who have sex with men in HPTN 067/ADAPT.
    J Acquir Immune Defic Syndr 2019.

  18. Bedimo RJ, Mar H, Bosch RJ, Drechsler H, et al.
    No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.
    J Acquir Immune Defic Syndr 2019.

  19. Haghighat R, Toska E, Cluver L, Gulaid L, et al.
    Transition Pathways out of Pediatric Care and Associated HIV Outcomes for Adolescents Living with HIV in South Africa.
    J Acquir Immune Defic Syndr 2019.

  20. Mills JC, Pence BW, Edmonds A, Adedimeji A, et al.
    The Impact of Cumulative Depression along the HIV Care Continuum in Women Living with HIV during the Era of Universal Antiretroviral Treatment.
    J Acquir Immune Defic Syndr 2019.

  21. Short WR, Sutton MY, Luo Q, Frazier EL, et al.
    Use of recommended preventive health care services and variations in HIV care among women with HIV in the United States, 2013-2014: Opportunities for expanded partnerships in support of ending the HIV epidemic.
    J Acquir Immune Defic Syndr 2019.

  22. Niu Q, Liu Z, Alamer E, Fan X, et al.
    Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.
    J Clin Invest 2019;130.

  23. Marston M, Gregson S.
    HIV, ART and fertility in sub-Saharan Africa: pieces still missing in the jigsaw puzzle.
    J Infect Dis 2019.

  24. Johnson LF, Mutemaringa T, Heekes A, Boulle A, et al.
    The effect of HIV and antiretroviral treatment on pregnancy rates in the Western Cape province of South Africa.
    J Infect Dis 2019.

  25. Bochnakian A, Zhen A, Zisoulis DG, Idica A, et al.
    Interferon-inducible miR-128 modulates HIV-1 replication by targeting TNPO3 mRNA.
    J Virol 2019.

  26. Styles TM, Gangadhara S, Reddy PBJ, Hicks S, et al.
    HIV C.1086 Envelope Gp140 Protein Boosts Following DNA/MVA Vaccination Fail to Enhance Heterologous Anti-V1V2 Antibody Response and Protection Against Clade C SHIV Challenge.
    J Virol 2019.

  27. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, et al.
    Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    N Engl J Med 2019.

  28. .
    Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    N Engl J Med 2019.

  29. Havlir DV, Doherty MC.
    Global HIV Treatment - Turning Headwinds to Tailwinds.
    N Engl J Med 2019.

  30. Redfield RR, Modi S, Moore CA, Delaney A, et al.
    Health Care Autonomy of Women Living with HIV.
    N Engl J Med 2019.

  31. Zash R, Holmes L, Diseko M, Jacobson DL, et al.
    Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
    N Engl J Med 2019.

  32. Goncales JP, Silva Junior JVJ, Lopes TRR, Tozetto-Mendoza TR, et al.
    Association of polymorphisms in NFkappaB1 promoter and NFkappaBIA gene with the development of antibodies against HHV-8 in HIV-infected individuals.
    Virology 2019;535:255-260.

  33. Iacobucci G.
    HIV: dolutegravir should be preferred treatment option in all populations, says WHO.
    BMJ 2019;366:l4831.


Display articles in


Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:



Amedeo HIV Infection

Five-Week Literature

19 August 2019

12 August 2019

05 August 2019

29 July 2019

22 July 2019


29 July 2019

Multidisciplinary Journal Club

  1. Croop R, Goadsby PJ, Stock DA, Conway CM, et al.
    Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Lancet. 2019 Jul 12. pii: S0140-6736(19)31606.

  2. Hayes RJ, Donnell D, Floyd S, Mandla N, et al.
    Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).
    N Engl J Med. 2019;381:207-218.

  3. Havlir DV, Balzer LB, Charlebois ED, Clark TD, et al.
    HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.
    N Engl J Med. 2019;381:219-229.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016